Antioxidant enzyme profile of two clinical isolates of Entamoeba histolytica varying in sensitivity to antiamoebic drugs

Figure 3 mRNA expression and activity levels of peroxiredoxin and FeSOD in clinical isolate 980 of Entamoeba histolytica during tatment with antiamoebic drugs. A: Graphical representation of densitometric data from semiquantitative RT-PCR analysis of Peroxiredoxin in clinical isolate 980, untreated (980 N) and after auranofin (980 A) and metronidazole treatment (980 M). Densitometric values are expressed as percent after normalizing with 18S rRNA. Each pair of columns show the data for untreated and treated isolate. Data are mean ± SE for three independent experiments. In case of auranofin treatment (^aP < 0.05); B: Graphical representation of densitometric data from semiquantitative RT-PCR analysis of FeSOD in clinical isolate 980. Densitometric values are expressed as percent after normalizing with 18S rRNA. Each pair of columns show the data for untreated and treated isolate. Data are mean ± SE for three independent experiments. In case of auranofin treatment (^aP < 0.05); C: Representative gel pictures of peroxiredoxin expression. 980 N: Untreated isolate; 980 A: Auranofin treated; 980 M: Metronidazole treated; M: Marker; +ve C: HM-1: IMSS cDNA used as +ve control; -ve C: cDNA from blank medim used as -ve control; D: Representative gel pictures of FeSOD expression. 989 N: Untreated isolate; 989 A: Auranofin treated; 989 M: Metronidazole treated; M: Marker; +ve C: HM-1: IMSS cDNA used as +ve control; -ve C: cDNA from blank medim used as -ve control.